DMXAA (Vadimezan): Mechanistic Insights into Tumor Vascul...

2025-09-18

Explore the multifaceted mechanisms of DMXAA (Vadimezan, AS-1404) as a vascular disrupting agent for cancer research, with a focus on its role as a DT-diaphorase inhibitor and apoptosis inducer in tumor endothelial cells. This article also examines emerging connections between vascular disruption and endothelial immune signaling in cancer biology.

Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Applic

2025-09-18

Angiotensin II Mechanisms, Clinical Applications, and Resear

2025-09-17

Amyloid Precursor C-Terminal Peptide Mechanistic Insights, C

2025-09-16

Beta-Sheet Breaker Peptide iAβ5 Mechanism, Clinical Value, a

2025-09-15

β-Interleukin I (163-171), Human Mechanisms, Clinical Applic

2025-09-13

Angiotensin 12 (1-5) Mechanisms, Clinical Value, and Researc

2025-09-12

GnRH Associated Peptide (GAP) (1-13), Human Mechanisms, Clin

2025-09-11

Epidermal Growth Factor Receptor Peptide (985-996) Mechanism

2025-09-10

Adrenorphin A Comprehensive Review of Its Mechanism, Clinica

2025-09-09

Amyloid Precursor C-Terminal Peptide Mechanisms, Clinical Ap

2025-09-08

alpha-Endorphin Mechanisms, Clinical Value, and Research Per

2025-09-05

Acetyl Angiotensinogen (1-14), Porcine Mechanisms, Clinical

2025-09-04

Angiotensin III (Human, Mouse) Mechanisms, Clinical Applicat

2025-09-03

[Ser25] Protein Kinase C (19-31) Mechanisms, Clinical Applic

2025-09-02